(LIVN) LivaNova PLC BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(LIVN) LivaNova PLC Complete Analysis Pack
See the Bigger Picture
This LivaNova PLC BCG Matrix is a company-focused strategy tool used to assess the portfolio’s products or business units across Stars, Cash Cows, Question Marks, and Dogs. The content on this page is a real preview of the actual analysis, so you can review the format and quality before buying. Purchase the full version to get the complete ready-to-use report instantly.
Stars
VNS Therapy System for drug-resistant epilepsy
VNS Therapy is LivaNova’s core neuromodulation franchise and its clearest high-share asset, with 100,000+ implants worldwide and a long physician base. The installed base drives recurring generator replacements every 5 to 10 years and steady follow-on use, which supports durable cash flow. Its leadership plus room for deeper epilepsy adoption makes it a Star in the BCG Matrix.
VNS Therapy for treatment-resistant depression
VNS Therapy for treatment-resistant depression expands LivaNova PLC’s market beyond epilepsy, where U.S. TRD affects about 30% of the 21 million adults with depression. The Verily biomarker work strengthens patient selection, and if adoption widens, this use case can support above-mature growth versus the core neuromodulation base.
VNS generator replacement cycle
LivaNova PLC's VNS replacement cycle is a strong Star trait: implanted generators create repeat sales when batteries near end of life, and hospitals already know the therapy, so conversion is easier than first-time adoption. This recurring base supports share and cash flow for reinvestment.
LivaNova PLC reported full-year 2024 VNS revenue growth in Neurostimulation, showing the installed base is still active and monetizing well.
Neuromodulation direct sales in the U.S. and Europe
LivaNova’s neuromodulation Stars unit uses direct sales in the U.S. and Europe to train physicians, support reimbursement, and keep accounts sticky. That matters in a business that still relies on high-touch clinical selling; LivaNova reported about $1.2 billion in net sales in 2024, and direct coverage helps defend share in its strongest therapy markets.
- Direct force lifts therapy education
- Reimbursement support speeds adoption
- Account retention strengthens share
- Best fit for core U.S./Europe markets
The model also improves control over pricing, follow-up, and switching risk, which is why it fits a Stars position in the BCG Matrix.
SenTiva VNS generator line
SenTiva is LivaNova's newer VNS generator line and sits at the core of its implantable neuromodulation franchise. With more than 1 million VNS patients treated globally, the line helps defend share against other neurostimulation options and supports a replacement cycle that can recur every 5 to 10 years as the installed base ages.
Newer generator line supports share defense.
Over 1 million VNS patients globally.
Replacement demand can recur every 5-10 years.
LivaNova’s VNS Franchise Powers Steady Growth and Cash Flow
LivaNova PLC's Stars are led by VNS Therapy and SenTiva, backed by 100,000+ implants, 1 million+ VNS patients, and a 5-10 year replacement cycle. The base drives repeat generator sales, supports share defense, and keeps cash flow steady. In 2024, Neurostimulation still showed revenue growth, so the franchise remains a core Star asset.
| Metric | Value |
|---|---|
| Implants | 100,000+ |
| VNS patients | 1,000,000+ |
| Replacement cycle | 5-10 years |
| 2024 result | Neurostimulation growth |
What is included in the product
Detailed Word Document
LivaNova PLC BCG Matrix shows which units to invest in, hold, or divest across Stars, Cash Cows, Question Marks, and Dogs.
Editable Excel File
Quick BCG view of LivaNova PLC to spot winners, dogs, and capital reallocation priorities fast
Reference Sources
Provides a clear source trail for LivaNova PLC, boosting credibility and helping decision-makers verify key claims fast.
Cash Cows
Cardiopulmonary segment
Cardiopulmonary is LivaNova PLC’s most mature segment, built on repeat demand from cardiac surgery and extracorporeal circulation. In 2025, it remained a steady cash engine rather than a fast-growth unit, with stable hospital-installed equipment and consumables supporting recurring sales. That profile fits a Cash Cow in the BCG Matrix: lower growth, but dependable margin and cash generation.
Oxygenators
Oxygenators are a Cash Cow for LivaNova PLC because they are standard, single-use bypass consumables, so hospitals reorder them often and keep using the same suppliers. That repeat demand and sticky hospital ties support steady margins in a mature market. LivaNova’s cardiopulmonary business has helped drive group revenue of about $1.2 billion in the latest reported year, showing the cash strength of this line.
Heart-lung machines
Heart-lung machines are a Cash Cow because they are high-ticket systems with 7- to 10-year replacement cycles, so hospitals buy slowly but steadily. The market is technical and regulated, which keeps rivals out and supports LivaNova PLC's installed base. That steady revenue helps fund R&D and other growth bets.
Perfusion systems
Perfusion systems are a mature cash cow for LivaNova PLC because they sit in the cardiac-surgery installed base and keep generating repeat demand for disposables, tubing, and service. Once a hospital buys the platform, the system can support years of follow-on revenue, so cash flow is steadier than in newer growth lines.
That matters in a low-growth segment: perfusion revenue is less about big unit growth and more about protecting share in a surgery workflow that is hard to replace. In BCG terms, the category fits a cash-generating role because installed systems help lock in recurring sales and operating leverage.
- Installed base drives repeat consumables
- Service revenue improves cash predictability
- Mature cardiac-surgery market limits growth
- Defend share, harvest cash flow
Disposables and accessories for cardiopulmonary use
Disposables and accessories for cardiopulmonary use are a classic cash cow for LivaNova PLC because demand tracks case volume, not rapid market growth. Once installed systems are in place, recurring consumables tend to generate steady, repeatable cash flow with low retooling risk and strong customer stickiness.
- Recurring demand follows procedures.
- Low growth, high cash conversion.
- Supports stable margins and funding.
LivaNova’s Cardiopulmonary Unit: Steady Cash Flow, Repeat Demand
LivaNova PLC’s cardiopulmonary unit is a Cash Cow: 2025 revenue was about $1.2 billion at group level, and the segment’s mature product mix keeps cash flow steady. Oxygenators, perfusion systems, and heart-lung machines sell on repeat replacement cycles, so growth is low but demand is sticky. The installed base supports margins and funds R&D.
| Cash cow driver | 2025 signal |
|---|---|
| Group revenue | About $1.2 billion |
| Demand pattern | Repeat consumables and service |
| Market profile | Mature, low-growth |
Full Version Awaits
LivaNova PLC Reference Sources
You're previewing the exact LivaNova PLC BCG Matrix report that will be delivered after purchase. What you see here is the same fully formatted document—no demo pages, no watermarks, no surprises. Once purchased, the full file is instantly available for download and ready to use for analysis or presentation.
Dogs
Legacy low-volume respiratory-support accessories
These legacy respiratory-support accessories fit the Dogs box: they sit outside LivaNova PLC's core cardiopulmonary and neuromodulation engines and likely add only a small slice of revenue. In a mature, low-growth niche, small SKUs can still tie up working capital, inventory, and service effort without strong scale benefits. That makes them weak capital allocators unless they protect installed-base sales or carry unusually high margins.
Older neuromodulation hardware generations
Older neuromodulation hardware generations at LivaNova PLC are losing momentum as customers shift to newer platforms, so growth is limited. They still add replacement and service revenue, but the share is smaller than the flagship VNS line. In BCG terms, this fits a Dog: low growth, narrower share, and mainly a cash-support role.
Small distributor-only geographies
Small distributor-only geographies are a Dogs fit for LivaNova PLC because third-party channels cut control over price, mix, and service. They also dilute leverage versus direct sales, so margins usually stay weak when scale is small. With low growth and low operating control, these markets add limited value and can trap capital.
Peripheral support parts with commoditized pricing
Peripheral support parts sit in the Dogs bucket because they are commodity-like and easy to compare on price. LivaNova PLC gets little differentiation here, so margins stay thin and the line matters more for keeping the product set complete than for growth.
- Intense price pressure
- Low product differentiation
- Thin margin profile
- Completeness over growth
Non-core support services tied to legacy installed base
LivaNova PLC's non-core support services tied to its legacy installed base fit a Dogs profile: they can keep customers on the platform, but they rarely drive fresh share gains. In FY2025, this kind of harvest business should be run for cash, not scale, especially when growth is flat and capital can earn more elsewhere.
- Retains base, but not new demand.
- Supports service revenue, not expansion.
- Best managed for cash harvest.
- Low growth, low share upside.
LivaNova’s Dogs: Small Share, Thin Margins, Cash-Only Role
Dogs at LivaNova PLC are legacy, low-growth, low-share assets that mostly harvest cash, not growth. In FY2025, they stayed peripheral to the core cardiopulmonary and neuromodulation platforms, with weak pricing power and thin margins.
| Metric | Dog signal |
|---|---|
| Growth | Low |
| Share | Narrow |
| Margin | Thin |
| Role | Cash harvest |
They can support installed-base service revenue, but capital use is hard to justify unless the line protects core sales.
Question Marks
VITARIA System for heart failure
VITARIA is still in clinical development, so it has no commercial share yet and stays a clear Question Mark in LivaNova PLC’s BCG view. Heart failure is a huge pool, affecting about 64 million people worldwide and driving more than $30 billion in annual U.S. direct costs, so the upside is real if clinical and regulatory progress turns into adoption. Until LivaNova proves durable use and reimbursement, the asset remains high-potential but unproven.
VNS Therapy for obstructive sleep apnea
OSA is a huge market, with about 1 billion adults affected worldwide, but LivaNova PLC’s VNS therapy is still early and not a mature franchise. Clinical data and regulatory wins will decide scale, because share is still uncertain. That puts it in Question Marks: big upside, but no clear commercial proof yet.
Advanced Circulatory Support platform
Temporary life-support demand is rising as ICUs add ECMO and pump capacity; the global ECMO market was about $0.7 billion in 2025 and is still growing fast. LivaNova’s Advanced Circulatory Support platform is smaller than leaders like Getinge and Abbott, so its share is limited. That mix of fast growth and weak share fits the Question Mark quadrant.
LifeSPARC-style temporary support systems
LifeSPARC-style temporary support systems fit the Question Marks bucket: they serve acute-care and extracorporeal rescue needs, where ICU volumes and ECMO adoption can lift demand. But scale is still small versus LivaNova PLC’s core cardiopulmonary business, so growth is promising yet not proven.
In 2024, LivaNova PLC reported total revenue of $1.28 billion, with Cardiopulmonary still the main engine, so LifeSPARC remains a niche bet. That makes it high-potential, but it needs faster hospital uptake and steadier procedure volumes to matter materially.
- Acute-care demand can spike fast.
- ICU use drives rescue-therapy adoption.
- Commercial scale stays relatively small.
Verily depression biomarker collaboration
Verily's depression biomarker work is still a research program, not a scaled revenue line, so it fits LivaNova PLC's Question Mark bucket. LivaNova PLC reported about $1.2 billion in 2024 revenue, but biomarker-led patient selection has no proven commercial pull yet. If it lifts VNS response and adoption, the upside could be material.
- Research stage, not sales stage
- May improve VNS patient selection
- Commercial proof is still missing
- High upside, low certainty
LivaNova’s High-Upside Question Marks Face a Make-or-Break 2025
LivaNova PLC's Question Marks are high-upside, low-share bets: VITARIA is still pre-revenue, OSA therapy faces a 1 billion-adult market, and Advanced Circulatory Support sits in a 2025 ECMO market near $0.7 billion. Growth is there, but clinical proof, reimbursement, and adoption still decide scale.
| Asset | 2025/2026 signal | BCG view |
|---|---|---|
| VITARIA | Pre-revenue | Question Mark |
| OSA | 1 billion adults | Question Mark |
| Advanced Circulatory Support | ECMO $0.7 billion | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.